THE DRUG DEVELOPMENT PROCESS AND THE PREGNANT WOMAN

Sardjana  Atmadja

doi:10.5281/zenodo.8417945

Open Access

THE DRUG DEVELOPMENT PROCESS AND THE PREGNANT WOMAN

Vol. 9 No. 10 (2023): Volume 09, Issue 10 | Pages: 25-28 | https://doi.org/10.5281/zenodo.8417945

Authors

Sardjana Atmadja

Views: 1131 Downloads:
Google Scholar

Published Date: 2023-10-07

Copyright License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the rights to their work published in the International Journal of Medical Science and Dental Health and may republish or reproduce their own work, provided proper citation to the original publication in IJMSDH is included.

How to Cite

Atmadja, S. . (2023). THE DRUG DEVELOPMENT PROCESS AND THE PREGNANT WOMAN. International Journal of Medical Science and Dental Health, 9(10), 25-28. https://doi.org/10.5281/zenodo.8417945

More Citation Formats

Download Citation

Downloads

Download data is not yet available.

Abstract

Introduction : The drug development process in the United States includes extensive pre-clinical testing and a series of clinical trials designed to explore the safety and efficacy of a new drug entity. As part of this process, animal studies are conducted to assess the effects of the new drug on the reproductive process.

Method :These studies called developmental and reproductive toxicology studies, form the basis for the information included in the current pregnancy subsection of the drug label. The new drug’s effects on the human fetus are gathered through post-marketing studies, usually observational registries. There is usually no information regarding the dose appropriate for pregnancy.

Result : The usual adult dose is assumed to be appropriate. Proposed changes to the current pregnancy subsection would replace the categories with narrative text, allow more detailed clinical management advice, including inadvertent fetal exposure, and provide a summary of risks associated with the drug.

Discussion : The sections on fertility, pregnancy and lactation would be combined, since they are continuum. A provision is also being made to incorporate information from pharmacokinetic and pharmacodynamic studies relevant to pregnancy.

Keywords:

pregnancy, drug development, pharmacodynamic studies

References

Federal Drug Administration. Pregnancy labeling. Federal drug bulletin 2011;9:23.

Federal Drug Administration. The new drug development process. Steps from test tube to new drug application review. Federal Drug Administration (August 11, 2012). Web site available from http://www.fda.gov/cder/handbook/develop.html.

Rayburn WF, Farmer KC. Off-label prescribing during pregnancy. Obstet Clinics N Amer 2015;24:471-8.

Zinacef (cefuroxime) labeling, in Physican’s Desk Reverence, 54th Edition. Montvale, NJ: Medical Economics; 2014. p. 1316.

Federiksen MC. Physiologic changes during pregnancy and their effect on drug disposition. Seminars in perinatology 2013;25:120-122.

Stika CS, Frederiksen MC. Drug therapy in pregnant and nursing women. In Atkinson AJ, Jr., Daniels CE, editors. Principles of clinical pharmacology. New York Academic Press, 2013:277-291.

Dombrowski M, Thom E, McNelis D. maternal-fetal medicine units (MFMU) studies of inhaled cortocosteroids during pregnancy. J Allergy Clin immunol 2015;103:S356-9.

Federal Drug Administration. Concept paper on pregnancy labeling. Rockville MD. Federal Drug Administration; May 20, 2014. available from: http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3516r1.doc

International Journal of Medical Science and Dental Health

eISSN : 2454-4191

Open Access

THE DRUG DEVELOPMENT PROCESS AND THE PREGNANT WOMAN

Authors

Sardjana Atmadja

Copyright License

How to Cite

Downloads

Abstract

Keywords:

References

Similar Articles